New Monthly Paliperidone Palmitate Injectable OK’d for Schizophrenia
The FDA approved a new monthly paliperidone palmitate (Erzofri) extended-release injectable suspension for treating schizophrenia in adults, Luye Pharma announced. An atypical antipsychotic, paliperidone palmitate